Apolipoprotein CIII inhibition in partial lipodystrophy

National Institute Of Diabetes And Digestive And Kidney Diseases

Investigators

Abstract

In the past fiscal year, this study was IRB approved, and initiated recruitment. To date, one subject has been randomized and completed the placebo-controlled portion of the study and continued to the open-label portion of the study. Recruitment of additional subjects is ongoing.